Find A Doctor

Uniting Eva Pharma and the medical community.

Eva Pharma brings you Egypt’s first online medical index. This index helps you find the right physician for your medical needs, close to your home, providing you with their contact information and address.

Browse By Type

Location


Speciality

Gender

Search By Name


 

EVA Pharma Launches its Immunity Booster Limitless Zinc® Tablets


Cairo, October 12, 2020 – EVA Pharma announces the launch of Limitless Zinc® tablets the newest member of its Limitless Naturals group of dietary supplements.

Limitless Zinc® is chelated zinc gluconate in 25 mg concentration which is easily absorbed and has no food or drug interactions. Limitless zinc supports a healthy immune system to defend against viruses and bacteria and promotes healthy skin, hair, and nails by supporting the body’s protein production and DNA formation. It also supports senses of smell, taste, and helps wounds heal.

“EVA Pharma is keen on covering all unmet patients’ needs to support their health and immunity through offering a variety of treatments,” said Dr. George Maher, global marketing director, “with a second spike of COVID19 wave approaching the world, the availability of such medications, vitamins, and minerals is considered a strong asset of the country’s efforts to combat the virus.”

Dr. Amgad El-Hadad, the consultant of allergy and immunology and head of the allergy and immunology center at the vaccination and immunization institute, pointed that “under ordinary circumstances zinc in foods as beans and nuts, almost 11 mg, is sufficient. But in such hard times like today, an adult needs a daily dose of 25 mg of zinc as prophylaxis to boost his/her immunity and 50 mg daily as part of the COVID-19 treatment protocol.”

“As part of the COVID19 treatment protocol, zinc plays an important role to inhibit the viral replication inside lung cells. Therefore zinc is recommended in prophylactic dose to prevent infection and activate the immune cells, while also advised for mild, moderate, severe or even carrier patients to boost their bodies’ immunity” explained Dr. Osama Abd El Latif, professor of allergy and immunology at Ain Shams University.

About EVA Pharma

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo, Egypt, while operating in more than 40 countries and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 41 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, EVA Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards.


U.S. Food and Drug Administration (FDA) Approved Remdesivir as the only Treatment for COVID-19


Cairo, October 25, 2020 – EVA Pharma announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Remdesivir for the treatment of COVID-19 patients requiring hospitalization.

Remdesivir had become now the first and only FDA-Approved treatment for COVID-19, as it was previously authorized by the FDA for emergency use to treat adult and pediatric hospitalized mild, moderate, and severe COVID-19 patients. The drug is now widely available in many countries as it is manufactured by EVA Pharma, a licensed manufacturer for Remdesivir-EVA Pharma according to an agreement with Gilead Sciences Inc. The agreement provides EVA Pharma with Gilead’s technology as well as manufacturing specifications and methods to accelerate the timeline of the production as soon as possible to export to 127 countries including Egypt.

As an antiviral drug, Remdesivir inhibit replication of SARS-CoV-2, the virus that causes COVID-19. The drug was investigated in three randomized control trials which showed clinically meaningful improvements with hospitalized COVID-19 patients as it shortened recovery time by five days.

Remdesivir has shown great results according to a clinical trial conducted by the U.S. National Institute of Allergy and Infectious Diseases investigating 1062 hospitalized COVID-19 patients. The study showed the median time to recovery was 10 days for the Remdesivir group compared to 15 days for the placebo group. Other trials have revealed a reduced “mortality rate” when patients are treated with Remdesivir.

“The results of Remdesivir use in Egypt match the global results,” said Dr. Hossam Hosny, head of the Anti-Coronavirus Scientific Committee at the Ministry of Health and Population, as he anticipated the expand in Remdesivir use last September in a scientific conference attended by Minister of Health Dr. Hala Zayed, and presidential advisor for health affairs, Dr. Mohamed Awad Tag El-Den.

 

About EVA Pharma

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo, Egypt while operating in more than 40 countries and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 42 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, EVA Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards.

download as pdf


EVA Pharma Launches the First Egyptian Generic for Type 2 Diabetes Treatment Diaflozimet® Tablets


Cairo, October 12, 2020 – EVA Pharma announced the launch of Diaflozimet® tablets after having received approval from the Egyptian Drug Authority (EDA). Diaflozimet® is the first Egyptian generic that contains (dapagliflozin and metformin hydrochloride extended-release), which is indicated for the treatment of adults with type 2 diabetes. The drug combines two anti-hyperglycemic agents with complementary mechanisms of action, dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, is a once-daily oral tablet. According to clinical studies, the combination is proven effective in rapidly controlling blood glucose levels with a 3% reduction of HbA1C, up to 3.3Kg weight reduction, blood pressure reduction and protecting the kidney, heart, blood vessels and liver against diabetes complications.

 

This is a very promising treatment from many aspects” said Dr. Abbas Oraby, professor of endocrinology and member of the National Committee for Endocrinology and Diabetes of the Ministry of Health and Population. “SGLT2 inhibitors release glucose from the body via the kidneys; in addition to recent studies proving its effectiveness in improving heart and kidney functions which is vital for diabetic patients since 50% of renal dialysis patients are diabetic. While metformin improves cardiac functions by 15% in addition to its abilities to lower blood glucose levels and to inhibit liver cirrhosis and the deterioration of insulin-producing beta cells in the pancreas. Thus the combination of both active ingredients supports a more personalized approach to disease management, as it reduces the number of pills the diabetic patients need to take leading to better compliance. Also, as EVA Pharma is producing Diaflozimet® in four concentrations, the physician has the choice of more personalized doses to his patients.”

Download as PDF


EVA Pharma starts export of COVID-19 Antiviral Avipiravir® Worldwide


Cairo, September 17, 2020, EVA Pharma, one of the major international pharmaceutical companies headquartered in Cairo, started the process of export of the first shipment of Avipiravir® (favipiravir). Thus becoming the first In the Region and continent to manufacture generic favipiravir of the Japanese antiviral Avigan, which is used to treat severe influenza, respiratory viruses, and mild to moderate COVID-19 patients. The announcement comes a few months following EVA Pharma’s success in producing and delivering another COVID-19 treatment, Remdesivir-EVA Pharma®, to various countries on four continents. The Egyptian drug manufacturer adds it to its antiviral portfolio and acquires all approvals to commercialize it in its home market

“We are very happy to launch Avipiravir® in Egypt and other markets across the world as we approach the winter season with expected influenza cases. This is a medicine that was made for influenza and has shown positive results for COVID patients in countries around the world and is available at a very accessible price” said Dr. Riad Armanious, EVA Pharma Chief Executive Officer

“Avipiravir® is an oral antiviral drug, selectively inhibits viral replication inside the human cells and was initially authorized in Japan in 2014 as a flu treatment and it is now approved for emergency use by the Russian Ministry of Health as a potential treatment of COVID-19,” said Dr. Ashraf Hatem, former Minister of Health and Population and member of the High Committee for Respiratory Viruses at the Ministry of Higher Education and Scientific Research.

The hope continues as Dr. Adel Khattab, professor of chest diseases at Ain Shams University and member of the High Committee for Respiratory Viruses at the Ministry of Higher Education and Scientific Research explains: “During the COVID-19 pandemic, the Japanese health authorities provided the product in more than 40 countries to include in global clinical trials. Favipiravir yielded positive outcomes, alleviating fever after 3 days of treatment with a significantly rapid reduction of viral load at 4 days of treatment, encouraging many countries to add favipiravir to their COVID-19 treatment protocol as is the case for China and India”

With the continuous positive findings of Avipiravir® and EVA Pharma’s accredited facilities, by the European Union and other global health accreditations, the company has the ability to meet all demands of Avipiravir® in global markets

 

About EVA Pharma

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo, Egypt while operating in more than 40 countries and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 41 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, Eva Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards.

download as pdf 


FDA Broadens Emergency Use Authorization for Remdesivir to Include All Hospitalized Patients for Treatment of COVID-19


 

Cairo, September 1, 2020 – “EVA Pharma’s Remdesivir achieves positive global results and we are equipped to cooperate with many authorities to provide all needed quantities in Egypt and more than 100 countries” Dr. Riad Armanious, CEO.

Remdesivir granted broader authorization by the American Food and Drug Administration upon recent clinical studies which show its effect on accelerating COVID-19 patients’ recovery, not only in severe cases but also in mild and moderate conditions. Now the emergency use authorization includes use for adults and pediatrics alike regardless of the severity of their symptoms.

The initial issuance of the (EUA) of Remdesivir by the FDA, which was also adopted by other countries with access to the drug, was limited to patients with severe disease, which was defined as patients with low oxygen levels or need oxygen therapy or more intensive breathing support as a mechanical ventilator.

In its recent report, the FDA stated that the known potential benefits of Remdesivir outweigh its risks. Thus, the broader use authorization of the antiviral is based on a clinical trial conducted by the U.S. National Institute of Allergy and Infectious Diseases investigating 1062 hospitalized COVID-19 patients. The study showed the median time to recovery was 10 days for the Remdesivir group compared to 15 days for the placebo group. Other clinical trials have revealed a reduced mortality rate to less than 2% when patients are treated with Remdesivir.

It is important to note that the new authorization restricts the use of Remdesivir under medical supervision and only for hospitalized patients.

“The results of Remdesivir use in Egypt match the global results” confirmed Dr. Hossam Hossny, head of the Anti-Coronavirus Scientific Committee at the Ministry of Health and Population in a scientific conference attended by Minister of Health Dr. Hala Zayed, and presidential advisor for health affairs, Dr. Mohamed Awad Tag El-Den. Hosny anticipated that WHO broadens the indication of Remdesivir use in the future based on its benefits to mild and moderate conditions.

Egypt is one of the first countries to benefit from the use of Remdesivir after the licensing agreement between Gilead Sciences and EVA Pharma, allowing the company to be one of the first 3 facilities to manufacture the drug worldwide.

Following the FDA report and clinical studies, Dr. Riad Armanious, EVA Pharma CEO, emphasized his company’s keenness to provide Egypt and more than 100 countries with their needs of Remdesivir-EVA Pharma®.

In his statement, Armanious said the global results of using Remdesivir-EVA Pharma® corresponds to the positive results of the aforementioned clinical studies. Affirming the drug’s effect in accelerating recovery time and reducing the need for mechanical ventilation and hospital care.

EVA Pharma’s CEO shared his company’s pride to be one of the first three facilities in the world to have worked on Remdesivir manufacturing, covering the Egyptian need of the drug to treat severe cases as well as the needs of a number of countries around the globe.

Armanious assured that EVA Pharma is equipped to cooperate with all the Egyptian governmental health authorities to provide all needed quantities of COVID-19 treatments and other medicines.

About Remdesivir®:

A new Antiviral drug developed by Gilead Company and produced by EVA Pharma in Egypt. Remdesivir got an FDA license for exceptional use (Emergency Use Authorization) for treating new COVID-19 patients in hospitals in the United States and the United Kingdom & now it got the FDA Broadens Emergency Use Authorization including mild and moderate, adult and pediatric COVID-19 patients. It has also been approved by the European Medicines Agency “EMA” for use in severe and critical COVID-19 cases and it’s already used in many European countries. It also obtained full approval for official use in Japan for critical cases.

 

download as pdf


Two Egyptian-Manufactured Medicines are Soon Entering Europe and Canada


 

Cairo, 27 August 2020 — EVA Pharma announces a license agreement with a global pharmaceutical company to co-manufacturer large quantities of two medicines,  one is an anticoagulant that is used with COVID-19 patients, and the other treats benign prostatic hyperplasia (BPH). The drugs will soon be available in European countries and in Canada.

The news comes after the conclusion of all registration procedures with the relevant authorities at the European Union and Canada, with ensuring the drugs are produced, in EVA Pharma’s manufacturing facilities in Egypt, under the best global pharmaceutical standards of quality.

The managing director of Elbe life sciences, which is located in Hamburg, Germany, and owned by EVA Pharma, Dr. Nicolas Boge, spoke on the company’s continuous abidance by the top global quality standards in pharmaceutical manufacturing for locally distributed products as well as exported products. He pointed to the company’s plan to expand its production of medicines to European countries and other places around the world in addition to making available new medicines first to be introduced to the Egyptian market.

Boge revealed: “the first drug, which will soon be available in the Canadian market, is apixaban, an anticoagulant that is used to prevent blood clotting. The medicine is used with some cardiovascular diseases and recently has been used to prevent coagulation with some COVID-19 patients. While the second drug is solifenacin, treatment of benign prostatic hyperplasia (BPH), and soon will be available in European countries.

The anticoagulant Apixatrack® and BPH treatment Solitract®, like many other EVA Pharma products, already available in the Egyptian market and have gained the trust of many physicians and patients alike.

download as pdf


EVA Pharma Talent Academy Equips 3 Thousands Pharmacy Students for the Job Market


Cairo, August 19, 2020 – EVA Pharma launched its “EVA Pharma Talent Academy” to train around 3 thousand students of the final years at pharmacy schools from universities around the nation. This step highlights the interest of actively participating in qualifying students to the job market and mining for the talented and outstanding students in order to offer them job opportunities.

In the 10th year of the annual summer internship organized by EVA Pharma under the name “Career Exploration”, Dr. George Saadan, Head of Human Resources department at EVA Pharma, mentioned that the training program has started in mid-July virtually due to the current coronavirus pandemic. Later on, according to a survey among the interns, around 1700 students were scheduled to field visits to the factories and field practice.

Such field training were held parallel to the theoretical lectures, at which activities the company was keen on providing protective equipment to the students.

Saadan added, “The training course takes 7 weeks featuring 28 lectures by an elite group of expert professors in different fields.” The lecturers were professors from the American University in Cairo, ESLSCA French university branch in Cairo, the Egyptian-Japanese University for science and technology, in addition to company leaders alongside practical hands-on field training.

EVA Pharma schedules the celebration of the summer internship completion at the end of August. The event will include presenting certificates to all interns with special rewards to the outstanding interns of the group.

Saadan clarified that the students are taught about the fundamentals which a pharmacist needs to know in his career. The training sharpens many skills, personal and professional, and covers many aspects like sales, marketing, decision-making, management, quality, and pharmaceutical manufacturing.

“During various pharmacy visits, the interns also participated in patients’ awareness on diseases and medications, including vitamins and its correlation to immunity support, common-cold, and flu medications, and other dietary supplements”, Saadan added.

Highlighting that the door constantly remains open for interns to come with their innovative ideas, Saadan pointed that the ones who come up with the most outstanding ideas receive job offers at the company as soon as they graduate; in addition to the opportunity, the company is offering to all interns, to gain career-related experiences which help them plan their future career pathway and make their decisions.

 

download as pdf


Remdesivir


EVA Pharma became a licensed manufacturer for the antiviral treatment “Remdesivir – EVA Pharma” under voluntary license, after reaching an agreement with Gilead Sciences Inc.

Remdesivir had been the first medication to be approved by the American Food and Drug Administration for Emergency Use Authorization (EUA) for the treatment of adult and pediatric patients with suspected or laboratory-confirmed SARS-CoV-2 infection and severe COVID-19. After that Remdesivir granted broader authorization by the FDA upon recent clinical studies which show its effect on accelerating COVID-19 patients’ recovery, in mild and moderate conditions not only for severe cases.

Also, it became the first medicine against COVID-19 to be recommended for authorization in the EU by the EMA.

Remdesivir has shown great results according to a clinical trial conducted by the U.S. National Institute of Allergy and Infectious Diseases investigating 1062 hospitalized COVID-19 patients. The study showed the median time to recovery was 10 days for the Remdesivir group compared to 15 days for the placebo group. Other trials have revealed a reduced “mortality rate” to less than 2% when patients are treated with Remdesivir.

EVA Pharma is gladly inviting you to be our partner in the battle against COVID-19, as we are opening doors for exporting Remdesivir-EVA Pharma to 126 countries.
For more info please contact us

Contact US

 


EVA Pharma Releases 500 Thousand Packs of the Analgesic and Antipyretic Drug Paracetamol under the Trade Name Stopadol®


 

Cairo, August 10, 2020 – EVA Pharma intends to reinforce the available quantities of Paracetamol supply in the Egyptian market by releasing 500 thousand packs of Stopadol®, as a part of its mission to offer affordable & high-quality medications.

 

Dr. Ibram Wagih, marketing manager, says there is an increased demand for the medicines containing the active constituent Paracetamol due to its efficacy in reducing fever and alleviating pain in many cases. Aside from its high efficacy in reducing the fever of common cold and flu patients, the drug was also recently found to have this effect with COVID-19 patients, further increasing the demand for it.

Wagih added, “EVA Pharma is keen on offering the Egyptian market a number of medicines used in the treatment of the novel COVID-19, such as immunity boosters and vitamins, as Ossofortin®, Limitless C zinc®, and Milga®, the antiviral Remdesivir-EVA Pharma®, the anticoagulant Apixatrack® and the antibiotic treatment Moxiflox® in addition to Stopadol®”

 

Wagih highlighted the use of Stopadol® in symptoms relief in coronavirus, common cold, and fever, as well as alleviating mild to moderate pain in cases of headache, migraine, neuropathy, toothaches, strep throat, menstrual symptoms, sprain, rheumatoid arthritis, sciatica, backaches (lumbago), fibrosis, myopathy, joint stiffness, and edema.

About EVA Pharma

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo, Egypt while operating in more than 40 countries and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 41 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, Eva Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards.

Download as PDF  


The Supreme Committee for Viruses Recognizes EVA Pharma as a Partner in the Eradication of Virus C in Egypt


Egyptian Study Proves Virus C Medicines Effective Against COVID-19

July 29, 2020, In light of World Hepatitis Day, celebrated on July 28th, the National Committee for Control of Viral Hepatitis, in collaboration with EVA Pharma, held a scientific conference on the updates of the fight against viral hepatitis.

During the conference, Dr. Gamal Esmat, vice chairman of the National Committee for Control of Viral Hepatitis of the Ministry of Health and Population, and the World Health Organization advisor, shared WHO’s goal to eliminate viral hepatitis globally by the year 2030. The goal which Egypt has already accomplished in virus C, Esmat highlighted “we are the first country to reach this rate of virus C elimination”.

Esmat commended EVA Pharma’s collaboration with Gilead Sciences to provide Egypt with a complete virus C treatment system, including high-quality medicines for relapsed cases and children.

As for the fight against hepatitis B, Esmat praised the novel medicine which EVA Pharma is planning its release soon. The medicine, as Esmat clarified, will benefit hepatitis B patients with renal dysfunction, unlike current treatments that have more load and kidney-related side effects.

On the margin of the conference, Esmat shared the positive results of an Egyptian study on the effect of HCV treatments on the novel coronavirus. The study, which was held at the faculty of sciences, Cairo University, has theoretically proved that HCV treatments as Nucleobuvir®, with active ingredient sofosbuvir, and Daclaviridin®, with active ingredient daclatasvir, accelerate the healing process, reduce the health effects and death rate of COVID-19.

Esmat added, after the conclusion of the study at Cairo’s faculty of sciences, 4 countries are now investigating the effects of HCV treatments on COVID-19. The countries are Egypt, Brazil, South Africa, and Iran.

Meanwhile, Dr. Riad Armanious, chief executive officer of EVA Pharma, said his company is keen on providing novel treatments to Egyptians; which allows the company to actively support the country’s quest to eliminate hepatitis C, in addition to its efforts to supply other antiviral treatments for hepatitis B, HIV, influenza, or coronavirus.

EVA Pharma owns the biggest pharmaceutical research center in the Middle East and Africa, Mounir Armanious Research Center (MARC), Armanious added. The company focuses on supporting scientific research and Egyptian researchers as well as the local manufacturing of active pharmaceutical ingredients and novel medicines.

While Dr. Amgad Talaat, general manager at EVA Pharma, said the company was a partner at the success of the president’s health campaign to eliminate hepatitis C. Talaat added, EVA Pharma, in collaboration with the Supreme Committee for Control of Viral Hepatitis and the Egyptian Society of Internal Medicine, will train more than a thousand hepatologist and infectious diseases specialist on the most recent treatments for hepatitis patients, as well as ultrasound diagnostic measures.

 

Download as PDF


Loading